Every 8-K that Omnicell Inc (OMCL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OMCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OMCL filings page.
Omnicell, Inc. reported strong second quarter 2026 results, with total revenues of $312 million, up $22 million, or 7% from the prior-year quarter. GAAP net income was $24 million, or $0.52 per diluted share, while non-GAAP net income was $44 million, or $0.94 per diluted share. Non-GAAP EBITDA reached $67 million, supported by demand for connected devices, SaaS and services, disciplined costs, and a $15 million refund of previously paid IEEPA tariffs that reduced product costs.
Operating cash flow in the quarter was $68 million, and as of June 30, 2026 Omnicell held $292 million in cash and cash equivalents, against $168 million of total debt and $350 million of undrawn revolver capacity. For 2026, the company guides total revenues to $1.225–$1.245 billion, non-GAAP EBITDA to $175–$185 million, and non-GAAP diluted EPS to $2.15–$2.30. Q3 2026 revenues are projected at $301–$307 million with non-GAAP EPS of $0.35–$0.43. Omnicell also announced the promotion of Nnamdi Njoku to President and Chief Operating Officer and added two senior pharmacy-focused leadership roles.
Omnicell, Inc. announced that its Board appointed Nnamdi Njoku as President of the Company, effective July 1, 2026, while he continues as Chief Operating Officer. Randall A. Lipps stepped down from the President role but remains Chief Executive Officer and Chairman of the Board with no compensation changes.
Njoku will lead Omnicell’s long-term growth strategy and innovation roadmap, focusing on scaling global operations and advancing initiatives such as the Omnicell Titan XT automated dispensing system and the cloud-native OmniSphere platform. To support his expanded role, the Compensation Committee approved a one-time equity award of restricted stock units with a target grant date value of approximately $500,000, vesting over three years, while his 2026 base salary remains $661,000 with a target cash bonus equal to 100% of salary.
Omnicell, Inc. reported results of its 2026 Annual Meeting and related governance changes. Stockholders approved an amendment to the 2009 Equity Incentive Plan that adds 1,600,000 shares of common stock authorized for issuance under the plan, increasing the pool available for equity-based compensation.
Stockholders elected Joanne B. Bauer, Robin G. Seim and Eileen J. Voynick as Class I directors to serve until the 2029 Annual Meeting. They also approved, on an advisory basis, named executive officer compensation, and ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The company amended its Amended and Restated Certificate of Incorporation to provide exculpation from personal liability for certain officers as permitted by Delaware law and to make minor non-substantive updates, following prior approval by the Board and stockholders.
Omnicell, Inc. reported a strong first quarter of 2026, with total revenues of $309.9 million, up 15% from the first quarter of 2025, driven by connected devices, technical services, SaaS and Expert Services, and consumables. GAAP results improved from a prior-year loss to net income of $11.4 million, or $0.25 per diluted share, while non-GAAP net income rose to $25.0 million, or $0.55 per diluted share. Non-GAAP EBITDA increased to $44.7 million, reflecting better profitability and cost discipline. The company generated $54.5 million of operating cash flow and ended March 31, 2026 with $239.2 million in cash and cash equivalents and $167.9 million of convertible senior notes. Omnicell raised its full year 2026 guidance for non-GAAP EBITDA to $153–$168 million and non-GAAP EPS to $1.80–$2.00, and now expects 2026 total revenues of $1.215–$1.255 billion.
Omnicell, Inc. filed a current report stating it issued a press release on February 5, 2026 announcing its financial results for the quarter and year ended December 31, 2025. The press release is provided as Exhibit 99.1 and is furnished, rather than filed, under securities laws.
Omnicell, Inc. furnished an update on performance, announcing third-quarter 2025 financial results and an update to full-year 2025 guidance via a press release. The company provided the details in Exhibit 99.1, referenced under Item 2.02 of the report. The information in Item 2.02 and Exhibit 99.1 is being furnished and not filed under the Exchange Act.
Omnicell, Inc. filed an 8-K to report that its board of directors adopted the company’s Fourth Amended and Restated Bylaws, effective September 30, 2025. The updated bylaws refine how shareholders can nominate directors and submit proposals at annual and special meetings, adding more detailed disclosure requirements for nominating or proposing shareholders, their nominees, and any individuals behind entity shareholders. The revisions also address matters related to Rule 14a-19 of the Exchange Act, clarify the company’s forum and personal jurisdiction provisions for certain lawsuits, and make various ministerial and conforming changes.
Omnicell, Inc. announced the appointment of Baird Radford as Executive Vice President and Chief Financial Officer in a press release dated August 25, 2025. The filing lists the press release as Exhibit 99.1 and includes the interactive data cover page as Exhibit 104. The document is signed by Corey J. Manley, Executive Vice President and Chief Legal and Administrative Officer.
The filing provides the appointment notice but contains no additional financial figures, background detail about the appointee, effective date beyond the press release date, or commentary on transition plans or compensation.